At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 201 enrolled
Drug / intervention
Ixekizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab, Placebo, and 1 other intervention for Plaque Psoriasis. Completed, enrolled 201 participants across 69 sites in 13 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesArgentina, Canada, Czechia, France, Germany, Hungary, Mexico, Netherlands, Poland, Puerto Rico, Russia, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartMar 2017
Primary CompletionFeb 2019
Study CompletionMar 2021
TodayJul 2026
First PostedMar 8, 2017
Enrollment StartMar 28, 2017
Primary CompletionFeb 7, 2019
Study CompletionMar 23, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.3 years ago
Interventions
Ixekizumabdrug
Administered SC
Placebodrug
Administered SC
Etanerceptdrug
Administered SC